Kodiak Sciences Inc. (KOD) Prices 6M Share Common Offering at $46/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Dell shares surge on record AI server bookings
- 'No panic anywhere' may be the problem, BofA strategists warn
- Kroger cuts same-store sales outlook, keeps earnings guidance
- AstraZeneca's camizestrant fails primary endpoint in breast cancer trial
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Pre-Open 12/03: (BOLD) (VRAY) (ALDX) Higher (CBL) (CARA) (CLF) Lower (more...)
December 3, 2019 9:16 AM ESTToday's Pre-Open Movers
Audentes Therapeutics, Inc. (NASDAQ: BOLD) 105% HIGHER; Astellas Pharma Inc. and Audentes Therapeutics, Inc. (NASDAQ: BOLD) today announced that they have entered into a definitive agreement for Astellas to acquire Audentes at a price of US$60.00 per share in cash, representing a total equity value of approximately US$3 billion.
CBL Properties (NYSE: CBL) 33% LOWER; announced that it is suspending all future dividends on its common stock, 7.375% Series D Cumulative Redeemable... More
After-Hours Movers 12/02: (BOLD) (VRAY) (ILPT) Higher; (CBL) (AGTC) (KOD) Lower (more...)
December 2, 2019 6:08 PM ESTToday's After-Hours Movers
Audentes Therapeutics, Inc. (NASDAQ: BOLD) 109% HIGHER; Astellas Pharma Inc. and Audentes Therapeutics, Inc. (NASDAQ: BOLD) today announced that they have entered into a definitive agreement for Astellas to acquire Audentes at a price of US$60.00 per share in cash, representing a total equity value of approximately US$3 billion.
CBL Properties (NYSE: CBL) 33% LOWER; announced that it is suspending all future dividends on its common stock, 7.375% Series D Cumulative Redeemable Preferred... More
Kodiak Sciences Inc. (KOD) Announces $250M Proposed Offering of Common Stock
December 2, 2019 5:01 PM ESTKodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that it has commenced an underwritten public offering of $250,000,000 of shares of its common stock. In connection with the proposed offering, Kodiak... More
Chardan Capital Positive on Kodiak Sciences' (KOD) $225M Baker Bros. Royalty Deal
December 2, 2019 11:44 AM ESTChardan Capital Markets analyst Gbola Amusa reiterated a Buy rating and $40.00 price target on Kodiak Sciences Inc. (NASDAQ: KOD) after the company announced the sale of a capped royalty right on global net sales of KSI-301 to Baker Bros. Advisors (BBA) for $225 million. Amusa views the news as positive, citing:
The royalty deal is less dilutive, e.g. if Kodiak views its valuation as... MoreKodiak Sciences Inc. (KOD) Halted on LUDP
December 2, 2019 10:12 AM ESTKodiak Sciences Inc. (NASDAQ: KOD) Halted on LUDP
... MoreKodiak Sciences Inc. (KOD) Climbs 130%
December 2, 2019 10:10 AM ESTKodiak Sciences Inc. (NASDAQ: KOD) Climbs 130%
... MoreKodiak Sciences Inc. (KOD) Reports Sale of Future Royalties on KSI-301 for $225M to Baker Bros. Advisors
December 2, 2019 6:08 AM ESTKodiak Sciences Inc. (NASDAQ: KOD) today announced that the Company has entered into a funding agreement to sell a capped royalty right on global net sales of KSI-301 to Baker Bros. Advisors for $225 million. KSI-301 is Kodiak's investigational therapy being developed for the treatment of retinal vascular diseases including age-related macular degeneration and diabetic eye diseases.
Under the terms of the agreement, Baker Bros. Advisors (BBA) purchased a capped 4.5% royalty on net sales of the Company's anti-VEGF antibody biopolymer conjugate therapy known as KSI-301 to be paid upon marketing approval in exchange for $225,000,000... More
